Live on XaptiqUGC NET Economics (Dec 2026) and IIT JAM Economics (EN) test series are now live on Xaptiq.View test series
EconomyIndian EconomyIndustryHuman CapitalCuet Pg Eco Indian

Private industry now funds more of India's R&D than the government

Private industry funded 51.8% of India's R&D spending in 2023-24 for the first time, and total R&D crossed 0.83% of GDP in 2021-22 — the highest since 2009-10 — according to the Department of Science and Technology's Research and Development Statistics 2025-26.

What happened

The Department of Science and Technology's (DST) Research and Development Statistics 2025-26 shows that India's R&D spending reached 0.83% of GDP in 2021-22, the first time it crossed 0.8% since 2009-10, and is estimated to approach 0.9% of GDP in 2025-26. Private industry's share of national R&D spending rose from 45.5% in 2021-22 to 51.8% in 2023-24 — the first time businesses outspent all levels of government combined. Transportation companies were the single largest industrial R&D investors at ₹39,137 crore in 2023-24, followed by drugs and pharmaceuticals (₹25,847 crore), biotechnology (₹10,321 crore), information technology (₹9,587 crore) and electrical and electronics (₹6,779 crore).

Context

The previous DST statistical compendium, released in 2020 with data up to 2018-19, had transport R&D at only around ₹14,000 crore and biotechnology and IT at much smaller shares. Since then, transport-sector R&D has almost tripled, biotech has emerged as one of India's largest research-intensive industries, and IT has entered the top corporate R&D spenders. The DST attributes the surge to a post-Covid 'realisation' by firms that R&D is critical to their future, and to stricter RBI disclosure requirements on R&D spends. Data comes from self-reported industry questionnaires, with methodology unchanged from prior editions.

Why it matters

The level of R&D spending matters — 0.83% of GDP in 2021-22 is the first time India crossed 0.8% since 2009-10, and 0.9% is now within reach — but the composition matters more. When government funds most of the R&D, output tilts toward defence, atomic energy and space programmes; when business enterprises take the lead, activity tilts toward commercialisable innovation in pharma, biotech and mobility. The workforce shift — private industry now employing more full-time-equivalent researchers than government institutions — signals a durable rerouting of scientific talent into the private sector, changing where the returns to public spending on higher education ultimately land.

Impact for India

  • Innovation-intensive sectors: transportation, pharmaceuticals, biotech and IT get identified as the corporate R&D engines, strengthening their case for targeted R&D-linked tax incentives and skilling schemes.
  • MSMEs and mid-tier firms: 90% of the reported R&D spend came from just around 500 companies out of nearly 8,000 in the DST database, flagging a very thin R&D base outside the top layer.
  • Scientific and Industrial Research Organisations (SIROs) and private universities: contributed ₹7,798 crore and ₹9,164 crore respectively of the ₹1.27 lakh crore private R&D pool in 2023-24, still small relative to business enterprises' ₹1.11 lakh crore.
  • Public research institutions: their falling share does not necessarily mean falling spending, but it does change India's basic-research pipeline calculus.
  • Policy and regulation: with RBI disclosure requirements already citing as a driver, more granular corporate reporting norms and R&D-linked incentives become more effective policy levers.

Key data

India's R&D expenditure, 2021-22: 0.83% of GDPFirst crossing of 0.8% since 2009-10
R&D expenditure estimate, 2025-26: Approaching 0.9% of GDP
Private industry share of national R&D: 51.8% in 2023-24Up from 45.5% in 2021-22
Transportation R&D, 2023-24: ₹39,137 croreUp from around ₹14,000 crore in 2018-19Largest industrial R&D contributor
Biotechnology R&D intensity: 16.8% of sales turnoverAmong the highest of any industrial sector
Concentration of corporate R&D: 90% from around 500 companiesOut of nearly 8,000 firms in the DST database

Concepts

R&D intensityResearch and development spending as a share of an entity's output — either GDP for a country or sales turnover for a firm or sector.India is closing in on 0.9% R&D-to-GDP; biotechnology firms are pushing 16.8% R&D-to-sales, showing how the ratio behaves at very different scales.
Gross Expenditure on R&D (GERD)Total spending on research and development performed within a country during a given year, by government, business enterprises, higher education and non-profits.The DST's R&D Statistics measure exactly this aggregate, and its share of GDP is the standard cross-country benchmark.
Business Enterprise Sector R&D (BERD)The share of GERD financed and performed by business firms, as opposed to government or academia.India's BERD share crossing government spending for the first time is the structural signal in this year's report.
Full-time equivalent (FTE) R&D personnelA conversion that counts every researcher's or technician's time by the share of it actually spent on R&D, so a part-time researcher counts as a fraction.The DST estimates private industry now employs more FTE R&D personnel than government institutions did in the previous survey round.

Stakeholders

Gains: Corporate R&D-intensive sectors (transport, pharma, biotech, IT)Identified as the country's leading corporate R&D contributors, strengthening their claim on R&D-linked policy support.
Gains: Biotechnology firmsSpent 16.8% of their sales turnover on R&D — among the highest research intensities of any industrial sector — validating the sector's innovation-led business model.
Gains: Researchers employed in business enterprisesPrivate industry now employs more full-time-equivalent R&D personnel than government institutions.

Practice Question — from the story

With reference to the Department of Science and Technology's Research and Development Statistics 2025-26, consider the following statements:

  1. Drugs and pharmaceuticals was the single largest industrial R&D contributor in 2023-24, ahead of the transportation sector.
  2. Private industry's share of national R&D spending fell below the government's share for the first time in 2023-24.

Which of the statements given above is/are correct?

  1. 1 only
  2. 2 only
  3. Both 1 and 2
  4. Neither 1 nor 2
Reveal answer & explanation

Answer: Neither 1 nor 2

  • Statement 1: Incorrect. Transportation was the single largest industrial R&D contributor at ₹39,137 crore; drugs and pharmaceuticals ranked second at ₹25,847 crore.
  • Statement 2: Incorrect. Private industry's share rose to 51.8% in 2023-24 — the first time businesses contributed more to R&D than all levels of government combined.

Therefore, the correct answer is Neither 1 nor 2.

Concept check — test your understanding

Two industries have very different R&D-to-sales ratios: biotechnology reports a high double-digit share of its turnover spent on R&D, while transportation reports a much smaller share even though transport firms spend the largest absolute rupee amount on R&D. What does this contrast most directly illustrate?

  1. That transportation firms are less innovative than biotech firms in every measurable sense.
  2. That government R&D subsidies flow disproportionately to biotechnology and away from transportation.
  3. That biotechnology firms have larger revenues than transportation firms, which mechanically raises their R&D-to-sales ratio.
  4. That R&D intensity — the ratio of R&D to sales — can be high in a small-revenue sector and low in a large-revenue sector, even when absolute spending goes the other way.
Reveal answer & explanation

Answer: D

  • R&D intensity is spending scaled by sales, so a sector with modest turnover but heavy research needs — like biotech — can show a very high ratio, while a large-turnover sector like transport can spend the biggest absolute rupee amount and still have a relatively small ratio.
  • A misreads the ratio as a universal ranking of 'innovation'; the article itself flags absolute spend and R&D intensity as separate measures.
  • B introduces a subsidy-flow claim not supported by the report and confuses the direction of causation.
  • C reverses the arithmetic — if biotech had larger revenues, its R&D-to-sales ratio would fall, not rise.